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Abstract
Alzheimer’s disease dementia (AD dementia) is one of the most common neurodegenerative diseases worldwide, with a growing
incidence during the last decades. Clinical diagnosis of cognitive impairment and presence of AD biomarkers have become
important issues for early and adequate treatment. We performed a systematic literature search and quality appraisal of AD
dementia guidelines, published between 2005 and 2011, which contained diagnostic recommendations on AD dementia. We also
analyzed diagnostic recommendations related to the use of brief cognitive tests, neuropsychological evaluation, and AD
biomarkers. Of the 537 retrieved references, 15 met the selection criteria. We found that Appraisal of Guidelines Research and
Evaluation (AGREE)-II domains such as applicability and editorial independence had the lowest scores. The wide variability on
assessment of quality of evidence and strength of recommendations were the main concerns identified regarding diagnostic
testing. Although the appropriate methodology for clinical practice guideline development is well known, the quality of diagnostic
AD dementia guidelines can be significantly improved.
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Background
The world population is rapidly aging, which causes a signifi-
cant increase in chronic and neurodegenerative diseases, with
serious consequences in terms of global public health. The
prevalence of diseases such as dementia is nearly 42 million
patients in 2012, with approximately 4.6 million new cases a
year.1 These figures would increase up to 300% by 2040, with
an impact on expenditure of over US$ 422 billion.1,2
Alzheimer’s disease dementia (AD dementia), the most
common dementia in the Western world, is defined as a cogni-
tive decline documented by standardized testing on 2 or more
domains, which interferes with daily function and represents
a decline in previous levels.3 Recently, the National Institute
of Neurological and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association
criteria have been updated and presented 3 different types of
AD dementia according to presence of core clinical criteria
only (probable), an atypical course without differential diagno-
sis (possible), or neuropathological evidence (definitive).4
The presence of cognitive impairment, especially in the
memory domain, is a fundamental part of the clinical criteria used
to diagnose AD dementia. This impairment must be detected and
diagnosed through a combination of clinical history analysis and
objective cognitive assessment by means of a brief mental evalua-
tion or comprehensive neuropsychological testing.4 The latter
reflects the clinical dimension of the disease and characterizes the
type of presentation. However, new trends in AD dementia
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